Literature DB >> 7781415

Current approach to malignant mesothelioma of the pleura.

J Aisner1.   

Abstract

Malignant mesothelioma of the pleura occurs primarily in individuals who were exposed to asbestos either in the workplace or home. The incidence of malignant mesothelioma is rising and, reflective of the malignancy's long latency period, is expected to continue to increase into the next century. Current treatment measures, including surgery, radiation therapy, chemotherapy, intrapleural therapy, and combined-modality therapies, have had varying impacts on survival. This paper explores current trends in the treatment of malignant pleural mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781415     DOI: 10.1378/chest.107.6_supplement.332s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

2.  Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study.

Authors:  K Segers; S Kumar-Singh; J Weyler; J Bogers; M Ramael; J Van Meerbeeck; E Van Marck
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Authors:  Qi Li; Wei Wang; Tadaaki Yamada; Kunio Matsumoto; Katsuya Sakai; Yoshimi Bando; Hisanori Uehara; Yasuhiko Nishioka; Saburo Sone; Shotaro Iwakiri; Kazumi Itoi; Teruhiro Utsugi; Kazuo Yasumoto; Seiji Yano
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

4.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma.

Authors:  Jennifer C C Hu; William Brookings; Malcolm C Aldridge
Journal:  J Gastrointest Cancer       Date:  2008-10-18

6.  Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

Authors:  Ayse Mavi; Sandip Basu; Tevfik F Cermik; Muammer Urhan; Mehdi Bathaii; Dhurairaj Thiruvenkatasamy; Mohamed Houseni; Simin Dadparvar; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-05-27       Impact factor: 3.488

7.  Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma.

Authors:  Abdurrahman Abakay; Abdullah C Tanrikulu; Muhammet Ali Kaplan; Mehmet Kucukoner; Ozlem Abakay; Hadice Sen; Abdurrahman Isikdogan; Abdurrahman Senyigit
Journal:  Lung India       Date:  2011-10

8.  Physician requests by patients with malignant pleural mesothelioma in Japan.

Authors:  Yasuko Nagamatsu; Isao Oze; Keisuke Aoe; Katsuyuki Hotta; Katsuya Kato; Junko Nakagawa; Keiko Hara; Takumi Kishimoto; Nobukazu Fujimoto
Journal:  BMC Cancer       Date:  2019-04-25       Impact factor: 4.430

9.  Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.

Authors:  Hiroto Yoneda; Hiroshi Nokihara; Atsushi Mitsuhashi; Ryohiko Ozaki; Yohei Yabuki; Hirokazu Ogino; Kenji Otsuka; Yasuhiko Nishioka
Journal:  BMC Pulm Med       Date:  2021-11-15       Impact factor: 3.317

Review 10.  Imaging Features of Various Benign and Malignant Tumors and Tumorlike Conditions of the Pleura: A Pictorial Review.

Authors:  June Young Bae; Yookyung Kim; Hyun Ji Kang; Hyeyoung Kwon; Sung Shine Shim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.